Cancer, the second leading cause of death worldwide, is more likely to respond to effective treatment if identified early before metastasizing, resulting in a greater probability of surviving. Some ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial We previously reported initial results of the ...

Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

ASCO's 2026 annual conference in Chicago featured cutting-edge research on treatment strategies for sarcomas such as GIST and ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy ...

Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology Alveolar soft part sarcoma (ASPS) is a rare, highly ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.